In this review we provide an evidence-based rationale for the incorporation of novel technologies for transurethral resection of bladder tumor in the setting of previously set standards.
Specific parameters for each model/scenario and knowledge-based rationale for the adaptation of all the PK and PD parameters are given in Supplementary Material online.
In this work, we have provided a structure-based rationale for the observed linker effects, using a modification of the CCG protocol, allowing reinterpretation of the JAA-F11 glycan array data (Table V).
If these volume-reducing mutations also stabilize the expanded conformation of αβ-tubulin in a GDP lattice, it would provide complementary support for our overpacking-based rationale for the β T238(A, S, V) effects.
Taken together, our data demonstrate a clear relationship between SJG-136-induced DNA ICL and cytotoxicity in primary CLL cells and offer a mechanism-based rationale for the increased DNA ICL observed in samples treated with the combination of SJG-136 and fludarabine compared to SJG-136 alone.
The recommendation for plasmapheresis in double positive patients is based on the rationale for the treatment of anti-GBM disease [ 38, 39].
We partly based our rationale for choosing this threshold on the opinions of prior consensus-based expert panels, that have proposed a 10% MCID for 1-year weight change patients with type 2 diabetes (while recognizing that weight reductions in type 2 diabetics are generally lower than non-diabetics) and a 15% MCID for statin uptake in patients with coronary disease [ 41, 42].
The DSM-5 workgroup based its rationale for dropping Substance Abuse on studies suggesting that there is no bright line boundary separating Abuse from Dependence.
Although the protocol is based on a solid rationale for the provision of water and is supported by scientific research, albeit limited, there is still much confusion in the clinic.
Based on the preclinical rationale for the combination of MK-2206 and trastuzumab, as well as promising preclinical results, we conducted a phase 1 trial to evaluate the QOD and QW dosing schedules from earlier trials and to determine the MTD and recommended phase 2 dose for MK-2206, administered in combination with standard doses of trastuzumab.
These assays provide compelling evidence for circulating monocytes and neutrophils as powerful negative prognostic factors for IL-2 based immunotherapy and establish a biological rationale for the addition of histamine to IL-2 in mRCC.
